{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:12:42Z","timestamp":1793041962543,"version":"4.5.0"},"reference-count":157,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Chimeric antigen receptor (CAR) T cell therapy has transformed the treatment landscape of relapsed\/refractory multiple myeloma. The current Food and Drug Administration approved CAR T cell therapies idecabtagene vicleucel and ciltacabtagene autoleucel both target B cell maturation antigen (BCMA), which is expressed on the surface of malignant plasma cells. Despite deep initial responses in most patients, relapse after anti-BCMA CAR T cell therapy is common. Investigations of acquired resistance to anti-BCMA CAR T cell therapy are underway. Meanwhile, other viable antigenic targets are being pursued, including G protein-coupled receptor class C group 5 member D (GPRC5D), signaling lymphocytic activation molecule family member 7 (SLAMF7), and CD38, among others. CAR T cells targeting these antigens, alone or in combination with anti-BCMA approaches, appear to be highly promising as they move from preclinical studies to early phase clinical trials. This review summarizes the current data with novel CAR T cell targets beyond BCMA that have the potential to enter the treatment landscape in the near future.<\/jats:p>","DOI":"10.3389\/fonc.2024.1398902","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:34:12Z","timestamp":1715301252000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Beyond BCMA: the next wave of CAR T cell therapy in multiple myeloma"],"prefix":"10.3389","volume":"14","author":[{"given":"Kevin","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Hashmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridevi","family":"Rajeeve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti\u2013B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen\u2013specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Invest"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"New Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1027385","article-title":"Immunotherapy for the treatment of multiple myeloma","volume":"13","author":"Boussi","year":"2022","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"New Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"New Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2015.10.003","article-title":"Chimeric antigen receptor T cell therapy: 25years in the making","volume":"30","author":"Gill","year":"2016","journal-title":"Blood Rev"},{"key":"B10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor\u2013modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010524","article-title":"Respiratory infections predominate after day 100 following B-cell maturation antigen-directed CAR T-cell therapy","volume":"7","author":"Little","year":"2023","journal-title":"Blood Adv"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017415","article-title":"How I treat cytopenias after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_397912","article-title":"High cost of chimeric antigen receptor T-cells: challenges and solutions","author":"Cliff","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"New Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20031330","article-title":"BCMA is essential for the survival of long-lived bone marrow plasma cells","volume":"199","author":"O\u2019Connor","year":"2004","journal-title":"J Exp Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment","volume":"127","author":"Tai","year":"2016","journal-title":"Blood J Am Soc Hematol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti\u2013B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8009","article-title":"CARTITUDE-1 final results: Phase 1b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma","volume":"41","author":"Lin","year":"2023","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02182-7","article-title":"Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results","volume":"29","author":"Mailankody","year":"2023","journal-title":"Nat Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1182\/blood-2023-182430","article-title":"Early safety results of P-BCMA-ALLO1, a fully allogeneic chimeric antigen receptor T-cell (CAR-T), in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"142","author":"Dholaria","year":"2023","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00246-2","article-title":"\u03b3-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial","volume":"24","author":"Cowan","year":"2023","journal-title":"Lancet Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007210","article-title":"Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma","volume":"7","author":"Frigault","year":"2023","journal-title":"Blood Adv"},{"key":"B25","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-022-01301-8","article-title":"Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)","volume":"15","author":"Zhao","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281628","article-title":"Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed\/refractory multiple myeloma: results from a phase I clinical trial","volume":"108","author":"Asherie","year":"2023","journal-title":"Haematologica"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005145","article-title":"Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed\/refractory multiple myeloma","volume":"10","author":"Qu","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136748","article-title":"Orvacabtagene autoleucel (orva-cel; JCARH125): A fully human BCMA-targeted second-generation CAR T cell product characterized by a predominant central memory phenotype with high in vitro and in vivo proliferative potential and sustained in vivo persistence","volume":"136","author":"Colonna","year":"2020","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8004","article-title":"Updated phase I study results of PHE885, a T-Charge manufactured BCMA-directed CAR-T cell therapy, for patients (pts) with r\/r multiple myeloma (RRMM)","volume":"41","author":"Sperling","year":"2023","journal-title":"J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"4845","DOI":"10.1182\/blood-2023-184373","article-title":"Three-year follow-up on efficacy and safety results from phase 1 lummicar study 1 of zevorcabtagene autoleucel in chinese patients with relapsed or refractory multiple myeloma","volume":"142","author":"Fu","year":"2023","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00222-X","article-title":"Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study","volume":"24","author":"Oliver-Cald\u00e9s","year":"2023","journal-title":"Lancet Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-160038","article-title":"Results from the first phase 1 clinical study of the B-cell Maturation Antigen (BCMA) nex T Chimeric Antigen Receptor (CAR) T cell therapy CC-98633\/BMS-986354 in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"140","author":"Costa","year":"2022","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-166465","article-title":"Updated results of fumanba-1: A phase 1b\/2 study of a novel fully human B-cell maturation antigen-specific CAR T cells (CT103A) in patients with relapsed and\/or refractory multiple myeloma","volume":"140","author":"Li","year":"2022","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an anti\u2013B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Invest"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-174364","article-title":"CD27-armored BCMA-CAR T cell (CBG-002) therapy for relapsed and refractory multiple myeloma: A phase I clinical trial","volume":"142","author":"Xu","year":"2023","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-178954","article-title":"Low target antigen expression mediates resistance to BCMA CAR T cell therapy","volume":"142","author":"Perica","year":"2023","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat Commun"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01245-5","article-title":"Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma","volume":"27","author":"Da Vi\u00e0","year":"2021","journal-title":"Nat Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0178-z","article-title":"Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells","volume":"558","author":"Fraietta","year":"2018","journal-title":"Nature"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abd4344","article-title":"A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity","volume":"6","author":"Boulch","year":"2021","journal-title":"Sci Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007445","article-title":"Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma","volume":"137","author":"Jain","year":"2021","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01960-7","article-title":"Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy","volume":"28","author":"Good","year":"2022","journal-title":"Nat Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01959-0","article-title":"Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma","volume":"28","author":"Haradhvala","year":"2022","journal-title":"Nat Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01916-x","article-title":"Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma","volume":"28","author":"Scholler","year":"2022","journal-title":"Nat Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4+ CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-1586","article-title":"Sequential single-cell transcriptional and protein marker profiling reveals TIGIT as a marker of CD19 CAR-T cell dysfunction in patients with non-hodgkin lymphoma","volume":"12","author":"Jackson","year":"2022","journal-title":"Cancer Discovery"},{"key":"B51","doi-asserted-by":"publisher","first-page":"3433","DOI":"10.1182\/blood-2023-182887","article-title":"Sequential scmultiomics of in vivo CAR-T cells allows characterization of transcriptional differences between patients, and identifies IL10 as a potential mechanism of resistance to CAR-T cells in MM","volume":"142","author":"Rodriguez-Madoz","year":"2023","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/blood-2023-187371","article-title":"Single cell multi-omic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma","volume":"142","author":"Merz","year":"2023","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","first-page":"3304","DOI":"10.1182\/blood-2023-191013","article-title":"Single Cell RNA Sequencing of Sequential Samples before and after BCMA-Directed CAR-T Reveal Features Associated with Non-Durable Response, Exhausted T-Cells and Decreased Expression of Genes Encoding Key Surface Targets in Particular in Patients with Extramedullary Disease","volume":"142","author":"Freeman","year":"2023","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-186395","article-title":"Multimodal single-cell transcriptomic and proteomic correlatives of patients outcomes following anti-BCMA cellular therapy with ciltacabtagene autoleucel (Cilta-cel) in relapsed multiple myeloma","volume":"142","author":"Vieira dos Santos","year":"2023","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012416","article-title":"CD4+ CAR-T cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR-T cell therapy","author":"Ledergor","year":"2024","journal-title":"Blood Adv"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-568881","article-title":"Pathogenesis beyond the cancer clone(s) in multiple myeloma","volume":"125","author":"Bianchi","year":"2015","journal-title":"Blood"},{"key":"B57","doi-asserted-by":"publisher","first-page":"4517","DOI":"10.1038\/s41467-022-32145-y","article-title":"The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states","volume":"13","author":"Rasche","year":"2022","journal-title":"Nat Commun"},{"key":"B58","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.1038\/s41467-019-11680-1","article-title":"Genomic landscape and chronological reconstruction of driver events in multiple myeloma","volume":"10","author":"Maura","year":"2019","journal-title":"Nat Commun"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006540","article-title":"Cancer immunoediting and immune dysregulation in multiple myeloma","volume":"136","author":"Nakamura","year":"2020","journal-title":"Blood"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-20-0227","article-title":"Determinants of response and mechanisms of resistance of CAR T-cell therapy in multiple myeloma","volume":"2","author":"van de Donk","year":"2021","journal-title":"Blood Cancer Discovery"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020571","article-title":"Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells","volume":"142","author":"Karschnia","year":"2023","journal-title":"Blood"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01564-7","article-title":"Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy","volume":"27","author":"Van Oekelen","year":"2021","journal-title":"Nat Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00512","article-title":"Chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma: moving into the future","volume":"41","author":"Holstein","year":"2023","journal-title":"J Clin Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2023.2276676","article-title":"BCMA CAR-T cells in multiple myeloma-ready for take-off","volume":"65","author":"Scheller","year":"2023","journal-title":"Leuk Lymphoma"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2022000396","article-title":"Cellular therapy for multiple myeloma: what\u2019s now and what\u2019s next","volume":"2022","author":"Rodriguez-Otero","year":"2022","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000983","article-title":"T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA","volume":"35","author":"van de Donk","year":"2023","journal-title":"Curr Opin Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2012.02679.x","article-title":"Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma","volume":"42","author":"Atamaniuk","year":"2012","journal-title":"Eur J Clin Invest"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci Transl Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N Engl J Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/nature11405","article-title":"An anatomically comprehensive atlas of the adult human brain transcriptome","volume":"489","author":"Hawrylycz","year":"2012","journal-title":"Nature"},{"key":"B71","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1182\/blood-2023-181857","article-title":"BMS-986393 (CC-95266), a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor (CAR) T-cell therapy for relapsed\/refractory multiple myeloma (RRMM): updated results from a phase 1 study","volume":"142","author":"Bal","year":"2023","journal-title":"Blood"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01824","article-title":"Anti-G protein-coupled receptor, class C group 5 member D chimeric antigen receptor T cells in patients with relapsed or refractory multiple myeloma: A single-arm, phase II Trial","volume":"41","author":"Xia","year":"2023","journal-title":"J Clin Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00372-6","article-title":"GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial","volume":"10","author":"Zhang","year":"2023","journal-title":"Lancet Haematol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1182\/blood-2023-179147","article-title":"Safety and efficacy of GPRC5D CAR T cell therapy in relapsed\/refractory multiple myeloma patients","volume":"142","author":"Li","year":"2023","journal-title":"Blood"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-02065-x","article-title":"Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma","volume":"38","author":"Li","year":"2023","journal-title":"Leukemia"},{"key":"B76","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s13045-021-01170-7","article-title":"A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma","volume":"14","author":"Mei","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13046-021-02214-z","article-title":"High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma","volume":"41","author":"Tang","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2030476","article-title":"A combination of humanized anti-BCMA and murine anti-CD38 CAR-T cell therapy in patients with relapsed or refractory multiple myeloma","volume":"63","author":"Zhang","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-4781(01)00197-X","article-title":"Cloning and characterization of a human orphan family C G-protein coupled receptor GPRC5D1GenBank accession Nos. for GPRC5C: AF207989, for Gprc5d: AF218809 and for GPRC5D: AF209923.1","volume":"1518","author":"Br\u00e4uner-Osborne","year":"2001","journal-title":"Biochim Biophys Acta (BBA) - Gene Structure Expression"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2308544","article-title":"Genetic basis of relapse after GPRC5D-targeted CAR T cells","volume":"389","author":"Mi","year":"2023","journal-title":"New Engl J Med"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00625-9","article-title":"Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation","volume":"4","author":"Derrien","year":"2023","journal-title":"Nat Cancer"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-20-0020","article-title":"Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape\u2013driven relapse in multiple myeloma","volume":"1","author":"Fern\u00e1ndez de Larrea","year":"2020","journal-title":"Blood Cancer Discovery"},{"key":"B83","doi-asserted-by":"publisher","first-page":"4679","DOI":"10.1182\/blood-2023-186150","article-title":"Identification of LPAR1\/LPAR5 as novel GPCR partners of GPRC5D for the efficient CAR-T therapy of multiple myeloma","volume":"142","author":"Zhou","year":"2023","journal-title":"Blood"},{"key":"B84","doi-asserted-by":"publisher","first-page":"3290","DOI":"10.1182\/blood-2023-189665","article-title":"Development of a novel, allogeneic GPRC5D-directed CAR for treatment of multiple myeloma patients","volume":"142","author":"Kinder","year":"2023","journal-title":"Blood"},{"key":"B85","doi-asserted-by":"publisher","first-page":"4802","DOI":"10.1182\/blood-2023-181613","article-title":"Efficacy of human iPSC-derived CAR-NK cells targeting multiple myeloma cells","volume":"142","author":"Fu","year":"2023","journal-title":"Blood"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-107292","article-title":"Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu","volume":"112","author":"Tai","year":"2008","journal-title":"Blood"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":"CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma","volume":"14","author":"Hsi","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med"},{"key":"B89","doi-asserted-by":"publisher","first-page":"3989","DOI":"10.1158\/1078-0432.CCR-13-2510","article-title":"Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells","volume":"20","author":"Chu","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-778423","article-title":"SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes","volume":"130","author":"Gogishvili","year":"2017","journal-title":"Blood"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.10.008","article-title":"Development of CAR T cells expressing a suicide gene plus a chimeric antigen receptor targeting signaling lymphocytic-activation molecule F7","volume":"29","author":"Amatya","year":"2021","journal-title":"Mol Ther"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01559-4","article-title":"CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells","volume":"36","author":"O\u2019Neal","year":"2022","journal-title":"Leukemia"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.3390\/biomedicines9101422","article-title":"Novel CS1 CAR-T cells and bispecific CS1-BCMA CAR-T cells effectively target multiple myeloma","volume":"9","author":"Golubovskaya","year":"2021","journal-title":"Biomedicines"},{"key":"B94","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1038\/s41467-020-16160-5","article-title":"Systematically optimized BCMA\/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma","volume":"11","author":"Zah","year":"2020","journal-title":"Nat Commun"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.302","article-title":"A compound chimeric antigen receptor strategy for targeting multiple myeloma","volume":"32","author":"Chen","year":"2018","journal-title":"Leukemia"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157950","article-title":"Preclinical activity of allogeneic CS1-specific CAR T-cells (UCARTCS1) in multiple myeloma","volume":"140","author":"Korst","year":"2022","journal-title":"Blood"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1309\/74R4TB90BUWH27JX","article-title":"Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma","volume":"121","author":"Lin","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-12-061812","article-title":"CD38\/CD19: a lipid raft\u2013dependent signaling complex in human B cells","volume":"109","author":"Deaglio","year":"2007","journal-title":"Blood"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"New Engl J Med"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2023","journal-title":"New Engl J Med"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017006866","article-title":"Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma","volume":"1","author":"Casneuf","year":"2017","journal-title":"Blood Adv"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181adaff1","article-title":"Activated T\u2013cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-hodgkin lymphoma","volume":"32","author":"Mihara","year":"2009","journal-title":"J Immunotherapy"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.205","article-title":"T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells","volume":"26","author":"Mihara","year":"2012","journal-title":"Leukemia"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.137620","article-title":"Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma","volume":"101","author":"Drent","year":"2016","journal-title":"Haematologica"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.8b00584","article-title":"Anti-multiple myeloma activity of nanobody-based anti-CD38 chimeric antigen receptor T cells","volume":"15","author":"An","year":"2018","journal-title":"Mol Pharm"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007059","article-title":"CD38 as a pan-hematologic target for chimeric antigen receptor T cells","volume":"7","author":"Glisovic-Aplenc","year":"2023","journal-title":"Blood Adv"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1038\/nm1101-1209","article-title":"Cyclic ADP-ribose production by CD38 regulates intracellular calcium release, extracellular calcium influx and chemotaxis in neutrophils and is required for bacterial clearance in vivo","volume":"7","author":"Partida-S\u00e1nchez","year":"2001","journal-title":"Nat Med"},{"key":"B109","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1182\/blood-2023-174742","article-title":"CD38 KO\/CD38-CAR human primary natural killer cells enhance cytotoxicity against CD38-expressing primary lymphoma, leukemia, and myeloma","volume":"142","author":"Troy","year":"2023","journal-title":"Blood"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2023.03.006","article-title":"Challenges in \u03b1CD38-chimeric antigen receptor (CAR)-expressing natural killer (NK) cell-based immunotherapy in multiple myeloma: Harnessing the CD38dim phenotype of cytokine-stimulated NK cells as a strategy to prevent fratricide","volume":"25","author":"Karvouni","year":"2023","journal-title":"Cytotherapy"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242417231","article-title":"Nicotinamide-expanded allogeneic natural killer cells with CD38 deletion, expressing an enhanced CD38 chimeric antigen receptor, target multiple myeloma cells","volume":"24","author":"Edri","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-761643","article-title":"CD138 mediates selection of mature plasma cells by regulating their survival","volume":"129","author":"McCarron","year":"2017","journal-title":"Blood"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.14670\/HH-29.177","article-title":"CD138 (syndecan-1) expression in health and disease","volume":"29","author":"Palaiologou","year":"2014","journal-title":"Histol Histopathol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.v10i24","article-title":"Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma","volume":"10","author":"Sun","year":"2019","journal-title":"Oncotarget"},{"key":"B115","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jocit.2014.11.001","article-title":"CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma","volume":"2","author":"Guo","year":"2016","journal-title":"J Cell Immunotherapy"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-0132","article-title":"Specific Targeting of Multiple Myeloma by Dual Split-signaling Chimeric Antigen Receptor T cells Directed against CD38 and CD138","volume":"29","author":"van der Schans","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.02.001","article-title":"Membrane-proximal epitope facilitates efficient T cell synapse formation by anti-fcRH5\/CD3 and is a requirement for myeloma cell killing","volume":"31","author":"Li","year":"2017","journal-title":"Cancer Cell"},{"key":"B118","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41408-021-00474-8","article-title":"Chromosome 1q21 abnormalities in multiple myeloma","volume":"11","author":"Schmidt","year":"2021","journal-title":"Blood Cancer J"},{"key":"B119","doi-asserted-by":"publisher","first-page":"3642","DOI":"10.1038\/s41467-023-39395-4","article-title":"Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma","volume":"14","author":"Jiang","year":"2023","journal-title":"Nat Commun"},{"key":"B120","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1182\/blood-2021-147983","article-title":"Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed\/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study","volume":"138","author":"Trudel","year":"2021","journal-title":"Blood"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.036814","article-title":"Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma","volume":"96","author":"Atanackovic","year":"2011","journal-title":"Haematologica"},{"key":"B122","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/s41467-020-14619-z","article-title":"CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide","volume":"11","author":"Radhakrishnan","year":"2020","journal-title":"Nat Commun"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.add7900","article-title":"Systematic single amino acid affinity tuning of CD229 CAR T cells retains efficacy against multiple myeloma and eliminates on-target off-tumor toxicity","volume":"15","author":"Vander Mause","year":"2023","journal-title":"Sci Transl Med"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-2043","article-title":"Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival","volume":"103","author":"Novak","year":"2004","journal-title":"Blood"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000703","article-title":"Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma","volume":"3","author":"Schmidts","year":"2019","journal-title":"Blood Adv"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-781351","article-title":"An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma","volume":"131","author":"Lee","year":"2018","journal-title":"Blood"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006699","article-title":"Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy","volume":"11","author":"Lee","year":"2023","journal-title":"J ImmunoTherapy Cancer"},{"key":"B128","doi-asserted-by":"publisher","first-page":"7509","DOI":"10.1038\/s41467-023-43416-7","article-title":"Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma","volume":"14","author":"Larson","year":"2023","journal-title":"Nat Commun"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1172\/JCI86000","article-title":"Clinical responses with T lymphocytes targeting Malignancy-associated \u03ba light chains","volume":"126","author":"Ramos","year":"2016","journal-title":"J Clin Invest"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0307","article-title":"Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML\/MDS and multiple myeloma","volume":"7","author":"Baumeister","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00378-7","article-title":"CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial","volume":"10","author":"Sallman","year":"2023","journal-title":"Lancet Haematol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-3096","article-title":"Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance","volume":"68","author":"Matsui","year":"2008","journal-title":"Cancer Res"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12563","article-title":"Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma","volume":"163","author":"Hajek","year":"2013","journal-title":"Br J Haematol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.120505","article-title":"Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma","volume":"3","author":"Garfall","year":"2018","journal-title":"JCI Insight"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000194","article-title":"Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma","volume":"3","author":"Stadtmauer","year":"2019","journal-title":"Blood Adv"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3910","article-title":"NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma","volume":"21","author":"Rapoport","year":"2015","journal-title":"Nat Med"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4431","article-title":"The activated conformation of integrin \u03b27 is a novel multiple myeloma\u2013specific target for CAR T cell therapy","volume":"23","author":"Hosen","year":"2017","journal-title":"Nat Med"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-04-493361","article-title":"CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma","volume":"122","author":"Casucci","year":"2013","journal-title":"Blood"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2012-3499","article-title":"CD56 targeted chimeric antigen receptors for immunotherapy of multiple myeloma","volume":"72","author":"Benjamin","year":"2012","journal-title":"Cancer Res"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-278218","article-title":"T cells redirected against CD70 for the immunotherapy of CD70-positive Malignancies","volume":"117","author":"Shaffer","year":"2011","journal-title":"Blood"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2010.21","article-title":"Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen","volume":"17","author":"Peinert","year":"2010","journal-title":"Gene Ther"},{"key":"B142","doi-asserted-by":"publisher","first-page":"4804","DOI":"10.1182\/blood-2023-182022","article-title":"Chimeric antigen receptor T cells targeting LILRB4, an immunoreceptor mediating T-cell suppression, are potently effective in multiple myeloma","volume":"142","author":"Di Meo","year":"2023","journal-title":"Blood"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1070353","article-title":"Innovation in BCMA CAR-T therapy: Building beyond the Model T","volume":"12","author":"Banerjee","year":"2022","journal-title":"Front Oncol"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.10.022","article-title":"Chimeric antigen receptor T cell therapy for myeloma: where are we now and what is needed to move chimeric antigen receptor T cells forward to earlier lines of therapy? Expert panel opinion from the american society for transplantation and cellular therapy","volume":"30","author":"Anderson","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"B145","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1182\/blood-2023-177669","article-title":"Co-expression of GPRC5D, fcRH5 and BCMA suggests that targeting more than one cell surface marker may be a viable strategy in relapsed\/refractory multiple myeloma (RRMM): biomarker results from the phase I study of forimtamig, a GPRC5DxCD3 bispecific antibody","volume":"142","author":"Dekhtiarenko","year":"2023","journal-title":"Blood"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0945","article-title":"Tuning the antigen density requirement for CAR T-cell activity","volume":"10","author":"Majzner","year":"2020","journal-title":"Cancer Discovery"},{"key":"B147","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1182\/blood-2023-180638","article-title":"Secondary genetic events impact the expression of key immunotargets on the surface of multiple myeloma cells","volume":"142","author":"Munawar","year":"2023","journal-title":"Blood"},{"key":"B148","doi-asserted-by":"publisher","first-page":"4683","DOI":"10.1182\/blood-2023-186980","article-title":"Impact of gamma-secretase inhibition on the multiple myeloma immune microenvironment","volume":"142","author":"Coffey","year":"2023","journal-title":"Blood"},{"key":"B149","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"},{"key":"B150","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1182\/blood-2023-187409","article-title":"Sequential T-cell engagement for myeloma (\u201cSTEM\u201d) trial: A phase 2 study of cevostamab consolidation following BCMA CAR T cell therapy","volume":"142","author":"Cohen","year":"2023","journal-title":"Blood"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-00323-z","article-title":"Recent advances and discoveries in the mechanisms and functions of CAR T cells","volume":"21","author":"Larson","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"B152","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41568-022-00505-x","article-title":"Rethinking cancer targeting strategies in the era of smart cell therapeutics","volume":"22","author":"Allen","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"B153","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cels.2020.08.002","article-title":"Discriminatory power of combinatorial antigen recognition in cancer T cell therapies","volume":"11","author":"Dannenfelser","year":"2020","journal-title":"Cell Syst"},{"key":"B154","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1158\/2159-8290.CD-20-0556","article-title":"Outlook for new CAR-based therapies with a focus on CAR NK cells: what lies beyond CAR-engineered T cells in the race against cancer","volume":"11","author":"Daher","year":"2021","journal-title":"Cancer Discovery"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010032","article-title":"Anti-myeloma efficacy of CAR-iNKT is enhanced with a long-acting IL-7, rhIL-7-hyFc","volume":"7","author":"O\u2019Neal","year":"2023","journal-title":"Blood Adv"},{"key":"B156","doi-asserted-by":"publisher","first-page":"3463","DOI":"10.1182\/blood-2023-190612","article-title":"CD70 CAR NK cells in the treatment of multiple myeloma","volume":"142","author":"Lin","year":"2023","journal-title":"Blood"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat Biotechnol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1398902\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:34:15Z","timestamp":1715301255000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1398902\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,10]]},"references-count":157,"alternative-id":["10.3389\/fonc.2024.1398902"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1398902","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,10]]},"article-number":"1398902"}}